Young Diane C. 4

What Happened
Diane C. Young, SVP and Chief Medical Officer of Celldex Therapeutics (CLDX), was granted a derivative award of 57,000 shares on June 25, 2026. The Form 4 reports the grant as a derivative acquisition (code A) at $0.00, meaning there was no immediate cash payment reported; the grant gives the right to acquire shares subject to vesting and plan terms.

Key Details

• Transaction date: June 25, 2026; Form 4 filed June 29, 2026 (timely filing).
• Instrument/type: Option/award reported as a derivative grant (code A).
• Quantity: 57,000 shares; reported price/value: $0.00 (no immediate cash outlay listed).
• Vesting: 25% vests on June 25, 2027; remaining 75% vests in equal quarterly installments over the subsequent 12 quarters.
• Plan: Granted pursuant to Celldex’s 2021 Omnibus Equity Incentive Plan.
• Shares owned after transaction: Not disclosed in the filing.

Context
This was a time‑based equity award (options) rather than an open‑market purchase or sale. Such grants are common for employee retention and compensation; they do not represent an immediate market buy or sell and carry vesting conditions before the holder can acquire shares.